Overview
RMD market data
Price History
RMD price chart
Valuation & Profitability
- P/E (TTM)
- 20.39 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $9.51 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.75 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 114.9% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $180.27 – $293.81 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $31K · P/B 6.34 · P/S 5.60.
Company News
Mizuho Maintains Outperform on ResMed, Lowers Price Target to $220Benzinga · Jul 15, 2026, 6:32 PM
ResMed shares are trading lower after Citigroup downgraded the stock from Buy to Neutral rating and lowered its price target from $270 to $235.Benzinga · Jul 13, 2026, 5:18 PM
Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For MondayBenzinga · Jul 13, 2026, 12:11 PM
Citigroup Downgrades ResMed to Neutral, Lowers Price Target to $235Benzinga · Jul 13, 2026, 11:43 AM
Jefferies Maintains Hold on ResMed, Lowers Price Target to $225Benzinga · Jul 10, 2026, 6:35 PM
ResMed Analyst Backs Portfolio ResetBenzinga · Jul 9, 2026, 6:05 PM
RBC Capital Maintains Outperform on ResMed, Lowers Price Target to $276Benzinga · Jul 8, 2026, 2:05 PM
ResMed Says Deal Valued At $490M All-Cash, Expected To Close In Q1 FY2027Benzinga · Jul 7, 2026, 9:35 PM
Resmed Strikes Agreement To Sell Its MatrixCare Operations To Frazier Healthcare Partners; Financial Terms UndisclosedBenzinga · Jul 7, 2026, 8:40 PM
Keybanc Maintains Overweight on ResMed, Lowers Price Target to $266Benzinga · Jun 22, 2026, 1:15 PM